

## **Speaker Biographies**



### **Ira Kalfus MD:**

Ira is the Chief Medical Officer of Aclipse Therapeutics. He also serves as Chief Medical Officer of Attune Pharmaceuticals. Previously, he was Chief Medical Officer at Thar Pharmaceuticals where he led the clinical development of T121 before Thar's acquisition by Grunenthal GmbH in a deal valued at \$275 million. He was also Medical Director at Redhill Therapeutics where he led the clinical development and FDA approval of Talicia®, now a commercial drug. Previously, he was VP of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze®, which was approved by the FDA. Lev was acquired by ViroPharma in a deal valued at \$617 million. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).



### **Raymond K. Houck:**

Raymond is the President and CEO of Aclipse Therapeutics, an orphan drug development company. Aclipse's lead asset M102 is for the treatment of ALS, Huntington's disease, Friederichs ataxia and Parkinson's disease. Previously, Mr. Houck was the CEO and co-founder of Thar Pharmaceuticals, acquired by Grunenthal GmbH in a deal valued at \$275 million. Thar was a clinical-stage pharmaceutical company developing a treatment for Complex Regional Pain Syndrome, an orphan disease with no approved FDA or EMA therapies. Before that, Mr. Houck was the CEO and co-founder of Automated Cell, a company focused on the discovery and development of antibody therapeutics for the treatment of cancer and before that, he co-founded Suprex Corporation, acquired by Teledyne, an analytical instrument and separation science company that was a pioneer in supercritical fluid chromatography. He has more than twenty issued and pending US and worldwide patents and holds a MS in industrial administration from Carnegie Mellon University and a BS in chemical engineering from the Pennsylvania State University.

If you are interested in receiving a copy of today's presentation please email [sk@gordiangroup.com](mailto:sk@gordiangroup.com) or [aab@gordiangroup.com](mailto:aab@gordiangroup.com).